LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

16.99 2.04

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.98

Max

17.43

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

106.172

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-4.08% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.31%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-9.6M

342M

Iepriekšējā atvēršanas cena

14.95

Iepriekšējā slēgšanas cena

16.99

Ziņu noskaņojums

By Acuity

25%

75%

44 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. nov. 22:42 UTC

Tirgus saruna

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 21:47 UTC

Tirgus saruna

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

2025. g. 21. nov. 21:43 UTC

Tirgus saruna

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

2025. g. 21. nov. 20:18 UTC

Tirgus saruna

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

2025. g. 21. nov. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

2025. g. 21. nov. 19:48 UTC

Tirgus saruna

Precious Metals Fall for the Week -- Market Talk

2025. g. 21. nov. 19:44 UTC

Peļņas

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

2025. g. 21. nov. 19:37 UTC

Tirgus saruna

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna
Peļņas

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

2025. g. 21. nov. 19:20 UTC

Tirgus saruna

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

2025. g. 21. nov. 18:44 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

2025. g. 21. nov. 18:37 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

2025. g. 21. nov. 18:34 UTC

Tirgus saruna
Peļņas

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

2025. g. 21. nov. 18:28 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 18:03 UTC

Tirgus saruna

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Intuit Seen on Path to Increase Growth -- Market Talk

2025. g. 21. nov. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 17:05 UTC

Tirgus saruna

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

2025. g. 21. nov. 16:56 UTC

Tirgus saruna

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

2025. g. 21. nov. 16:47 UTC

Tirgus saruna

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

2025. g. 21. nov. 16:35 UTC

Iegādes, apvienošanās, pārņemšana

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

2025. g. 21. nov. 16:09 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 15:59 UTC

Tirgus saruna

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

2025. g. 21. nov. 15:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. nov. 15:23 UTC

Tirgus saruna

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

2025. g. 21. nov. 15:17 UTC

Tirgus saruna

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-4.08% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -4.08%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

44 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat